Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462240 | 0.94 | MCHR1 (0.55) | MCHR1KCNH2HRH3 | |
| SCHEMBL502539 | 0.87 | MCHR1 (0.61) | MCHR1KCNH2HRH3 | |
| SCHEMBL2891016 | 0.82 | MCHR1 (0.79) | MCHR1KCNH2 | |
| SCHEMBL2891237 | 0.82 | MCHR1 (0.79) | MCHR1KCNH2 | |
| SCHEMBL13290234 | 0.78 | MCHR1 (0.58) | MCHR1KCNH2HRH3 | |
| SCHEMBL1002637 | 0.78 | MCHR1 (0.65) | MCHR1KCNH2HRH3 | |
| SCHEMBL2891110 | 0.77 | MCHR1 (0.61) | MCHR1KCNH2HRH3 | |
| SCHEMBL2571449 | 0.77 | MCHR1 (0.66) | MCHR1KCNH2HRH3 | |
| SCHEMBL1003583 | 0.76 | MCHR1 (0.62) | MCHR1KCNH2HRH3 | |
| SCHEMBL1004916 | 0.76 | MCHR1 (0.65) | MCHR1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924343-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-2906040-B1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3055288-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-2887807-B1 | BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2888007-B1 | BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES USEFUL AS AMP-ACTIVATED PROTEIN KINASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-3068768-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2888006-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES USEFUL AS AMPK ACTIVATORS | MERCK SHARP & DOHME (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2888005-B1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-2888008-B1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20080085926-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2008-04-10 | — | — | US | disclosed |
| WO-2008039418-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039327-A2 | METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008024284-A2 | SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007136571-A1 | PRO-DRUGS OF TERTIARY ALCOHOLS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007120718-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120688-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244048-A1 | Neuromedin U receptor agonists and uses thereof | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| WO-2007064566-A2 | HETEROCYCLE-SUBSTITUTED 3-ALKYL AZETIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007041052-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085926-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | GCGR, GLP1R, GPR119 | MCHR1 354/4885KCNH2 2388/4885HRH3 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.